OM:BIOA BBiotechs
Assessing BioArctic (OM:BIOA B) Valuation After New Lecanemab Data And Regulatory Milestones
Eisai’s latest conference data on lecanemab, along with updates on subcutaneous formulations and regulatory filings, has put BioArctic (OM:BIOA B) back in focus for investors watching neurological drug developers.
See our latest analysis for BioArctic.
The latest lecanemab updates arrive after a 12.9% 1 month share price return and a 5.3% 3 month share price return, while the 1 year total shareholder return of 86.6% shows strong longer term momentum building around BioArctic’s neurology...